Elamipretide
- Generic Name
- Elamipretide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H49N9O5
- CAS Number
- 736992-21-5
- Unique Ingredient Identifier
- 87GWG91S09
- Background
Elamipretide has been used in trials studying the treatment of Leber's Hereditary Optic Neuropathy.
- Associated Conditions
- -
- Associated Therapies
- -
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06373731
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Barnet Dulaney Perkins Eye Center, Sun City, Arizona, United States
FRDA Investigator Initiated Study (IIS) With Elamipretide
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 20
- Registration Number
- NCT05168774
- Locations
- 🇺🇸
Children's Hospital of Philadelphia - Neurology, Philadelphia, Pennsylvania, United States
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05162768
- Locations
- 🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸University of Pittsburgh School of Medicine Children's Hospital of Pittsburgh of UPMC Department of Genetics, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
An Intermediate Size Expanded Access Protocol of Elamipretide
- Conditions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Registration Number
- NCT04689360
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03098797
- Locations
- 🇺🇸
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02976038
- Locations
- 🇺🇸
University of California, San Diego, California, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 308
- Registration Number
- NCT02914665
- Locations
- 🇬🇧
Torbay Hospital, Torquay, United Kingdom
🇪🇸Hospital ClÃnico San Carlos, Madrid, Spain
🇪🇸Hospital Universitario de Bellvitge, Barcelona, Spain
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02848313
- Locations
- 🇺🇸
Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center), Durham, North Carolina, United States
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02814097
- Locations
- 🇷🇸
Clinical Center Niš, Clinic for Cardiology, Niš, Serbia
🇷🇸Clinical Hospital Center "Dr Dragiša Mišović-Dedinje", Department of Cardiology, Belgrade, Serbia
🇷🇸Clinical Hospital Center "Bežanijska Kosa", Department of Cardiology, Belgrade, Serbia
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02805790
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Diego, California, United States
🇺🇸Children's Hospital of Pittsburg of UPMC, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.